T2 Biosystems Inc. (TTOO)

6.63
NASDAQ : Health Technology
Prev Close 6.90
Day Low/High 6.60 / 6.94
52 Wk Low/High 2.53 / 9.98
Avg Volume 760.80K
Exchange NASDAQ
Shares Outstanding 43.03M
Market Cap 296.94M
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

3 Busted IPOs with 10-Bagger Potential

3 Busted IPOs with 10-Bagger Potential

Verastem Inc., T2 Biosystems Inc. and Resonant Inc. have great long-term growth prospects.

Antimicrobials Working Group Highlights Member Company Participation At ASM Microbe 2018

Antimicrobials Working Group Highlights Member Company Participation At ASM Microbe 2018

88 Presentations by Coalition Members During the Annual Meeting

How to Manage Risk in Biotech Stocks

How to Manage Risk in Biotech Stocks

T2 Biosystems' recent run-up on a positive event provides an important lesson for biotech investors.

Two Antibiotic Plays

Two Antibiotic Plays

They may not get all the attention, but antibiotic drugs are increasingly important.

How to Manage Risk in Biotech

How to Manage Risk in Biotech

T2 Biosystems used the run-up on a positive event - an FDA approval - to raise additional capital.

Interesting TTOO Put And Call Options For July 20th

Investors in T2 Biosystems Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TTOO options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

3 of My Favorite Medical Diagnostic Plays

3 of My Favorite Medical Diagnostic Plays

These equities have been in rally mode since April.

First Week Of November 16th Options Trading For T2 Biosystems (TTOO)

Investors in T2 Biosystems Inc saw new options begin trading this week, for the November 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 190 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TTOO Crosses Above Average Analyst Target

In recent trading, shares of T2 Biosystems Inc have crossed above the average analyst 12-month target price of $6.17, changing hands for $6.91/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Antimicrobials Working Group Highlights Member Company Participation At The 28th European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID)

71 Abstracts to be Presented by Coalition Members During the Annual Meeting

Multiple New Studies Demonstrate T2 Biosystems' Diagnostics Improve Detection Of Sepsis Causing Pathogens Over Blood Culture-based Diagnostics

Multiple New Studies Demonstrate T2 Biosystems' Diagnostics Improve Detection Of Sepsis Causing Pathogens Over Blood Culture-based Diagnostics

U.S. and EU studies demonstrate that T2Dx diagnostics enable getting patients on the right therapy faster, improving outcomes, enhancing stewardship, and reducing the cost of care

T2 Biosystems Reports Fourth Quarter And Full-Year 2017 Financial Results And Business Update

T2 Biosystems Reports Fourth Quarter And Full-Year 2017 Financial Results And Business Update

Quarterly Product Revenue Up 125% Year-Over-Year and 76% Over the Prior Quarter

T2 Biosystems Awarded Up To $2 Million By CARB-X To Support Development Of New Tests On The T2Dx Instrument For Drug-Resistant Bacteria

T2 Biosystems Awarded Up To $2 Million By CARB-X To Support Development Of New Tests On The T2Dx Instrument For Drug-Resistant Bacteria

T2 Biosystems Awarded Up To $2 Million by CARB-X to Support Development of New Tests on the T2Dx Instrument for Drug-Resistant Bacteria

TTOO Crosses Above Average Analyst Target

TTOO Crosses Above Average Analyst Target

In recent trading, shares of T2 Biosystems Inc have crossed above the average analyst 12-month target price of $5.25, changing hands for $6.36/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

3 Biotech Stocks I Love for March (Celgene Is One of Them)

3 Biotech Stocks I Love for March (Celgene Is One of Them)

These biotech names are all great buys on dips. Notably Celgene, which is fresh off a terrible trading session.

3 Promising Biotech Stocks to Buy on Dips

3 Promising Biotech Stocks to Buy on Dips

From ANI Pharmaceuticals to T2 Biosystems, these names look good.

Three Biotech Opportunities

Three Biotech Opportunities

Celgene, ANI and T2 are seeing attractive entry points.

Two New Studies Demonstrate T2Candida's Advantages Over Current Diagnostic Testing

Two New Studies Demonstrate T2Candida's Advantages Over Current Diagnostic Testing

Studies demonstrate T2Candida identifies infections missed by blood culture and the opportunity for faster targeted therapy

TTOO Crosses Above Average Analyst Target

TTOO Crosses Above Average Analyst Target

In recent trading, shares of T2 Biosystems Inc have crossed above the average analyst 12-month target price of $5.25, changing hands for $5.56/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

After Roche's acquisition of Ignyta, I have high hopes for these other two names in 2018.

2 Biotech 'Busted IPOs' to Watch in 2018

2 Biotech 'Busted IPOs' to Watch in 2018

Are these names the next 'Ignytas'?

TheStreet Quant Rating: D- (Sell)